Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease-Reference-Cited by-同舟云学术

Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease

Published:2015-12-18 Issue:3 Volume:65 Page:245-260
ISSN:1023-3830
Container-title:Inflammation Research
language:en
Short-container-title:Inflamm. Res.

Author:

Ichikawa Nobuki,Yamashita Kenichiro,Funakoshi Tohru,Ichihara Shin,Fukai Moto,Ogura Masaomi,Kobayashi Nozomi,Zaitsu Masaaki,Yoshida Tadashi,Shibasaki Susumu,Koshizuka Yasuyuki,Tsunetoshi Yusuke,Sato Masanori,Einama Takahiro,Ozaki Michitaka,Umezawa Kazuo,Suzuki Tomomi,Todo Satoru

Funder

Japan Society for the Promotion of Science

Promotion of Fundamental Studies in Health Sciences initiative of the National Institute of Biomedical Innovation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology

Link

http://link.springer.com/content/pdf/10.1007/s00011-015-0911-0.pdf

Reference37 articles.

1. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442–7.

2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40.